Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Prescribing off-label: It’s gotten out of control

Allen Frances, MD
Meds
February 5, 2015
146 Shares
Share
Tweet
Share

Doctors prescribe way too many medicines for patients who don’t really need them. A lot of the pressure comes from intense drug company marketing. Some comes from patients who aren’t happy leaving the office without a pill. And doctors have too little time with each patient to explain non-pill solutions to problems. Wild prescribing is not new. For thousands of years, doctors have given patients useless (and often quite harmful) drugs and patients have taken them.

Modern medicine was meant to be different — it would be based on scientific evidence that could tease out real effect from placebo effect. Unfortunately, evidence-based medicine is only as good as the evidence it is based on. And in many instances our evidence is not very good because it comes from biased drug company studies.

This is particularly true for the “off-label” prescription of medicines — use based not on the systematic study required for an FDA indication. Off-label prescribing is the wild west of medicine — any doctor can prescribe any drug for any problem.

Kim Witczak became involved as an ardent drug safety advocate after the death of her husband, Tim “Woody” Witczak, in 2003 as a result of a drug side effect that had not been disclosed to him. She has taken her personal experience and launched a national drug safety campaign.

“Doctors routinely give powerful drugs off-label to their patients, without strong scientific evidence proving the drugs will be safe or effective, and sometimes despite warnings that such prescribing could cause serious harm.

All the while, patients have no idea that the drug that’s being recommended to them does NOT have FDA approval for the particular condition. They just assume and trust their doctor.

Once a drug has been approved for sale for one purpose, physicians are free to prescribe it for any other purpose. They are not limited to official, FDA-approved indications. Off-label prescription use is very common. Up to one-fifth of all drugs are prescribed off-label and amongst psychiatric drugs, off-label use rises to 31 percent.

A recent study reveals that one-third of children in foster care diagnosed with ADHD have been treated off-label with an atypical antipsychotic medication. As a parent, would you consent to your child being prescribed an antipsychotic medication? The name alone should raise a red flag. And most atypical antipsychotics are NOT approved by the FDA for use by children.

Drugs are often used off-label, with nearly 80 percent of off-label prescriptions lacking “strong scientific evidence,” which means we do not know if their risks outweigh their benefits. Ultimately, it’s buyer beware.

It’s one thing if you have a rare disease and are desperate to try something that might offer hope. It’s another thing if you went to your doctor because you’re having trouble sleeping due to stress of a new job. Again, it’s a fine (yet potentially deadly) line patients are walking. We need to be told if the FDA has approved the product or if it’s being used off-label based on an article that appeared in some journal. Otherwise, we are just guinea pigs.

The FDA may soon make matters worse. It is considering new policies on distributing reprints of medical and scientific journal publications. In its new draft guidance entitled, “Distributing Scientific and Medical Publications on Unapproved New Uses-Recommended Practices.” The drug industry will be allowed to distribute journal articles and clinical practice guidelines (CPGs) regarding off-label use of their products to the medical community. This is basically a loophole for the pharmaceutical companies to promote their products off-label.

In recent years, over $13 billion in fines have been paid by major drug companies to settle lawsuits against them for their fraudulent marketing practices, including off-label promotion of their drugs/devices not approved by the FDA.

It’s a fine line between the drug company informing doctors about a new potential benefit in an off-label indication and the illegal promotion of a product for increasing sales.

In my opinion, this new guidance sends mixed messages. On the one hand, the FDA states that it “recognizes the value to health care professionals of truthful and non-misleading scientific or medical publications on unapproved new uses.”

But as everyone knows, medical journal articles are often biased because the authors or ghostwriters are paid by the company whose product is being studied. This should be very concerning to the doctors and patients alike.

Now more than ever, Informed consent is needed. It’s a great opportunity for patients and/or their caregivers to have an intentional conversation with their doctor about their medications. Armed with ALL the information, including if the drug is being used off-label, patients are then able to make an educated and informed decision about their drugs.

Sure seems like we could all get behind this concept and demand informed consent for drugs being given off-label. It just makes common sense for everyone, patients, and doctors, alike.”

Thanks, Kim. This is a great suggestion that I would extend even further. Why not require doctors to get written informed consent from their patients for all use of medication? This would make for much better-informed consumers and reduce careless over prescription of medication.

Off-label prescribing is much better for drug company profits than for patient welfare. Using medicines for unapproved uses on balance probably does much more harm than good. The doctor has no reason to think the medicine will work, every reason to know it will have side effects. Prescribing for indicated uses is overdone, prescribing for off-label use is rarely justified.

It would be a great mistake for the FDA to loosen its already weak control over drug company salesmanship. Drug companies have in past sustained large fines for illegal off-label marketing because the rewards are so great. FDA would be opening the gates to even more unscrupulous drug marketing. We need to restrict misleading marketing not promote it.

The argument that drug sales people are educating physicians doesn’t pass the laugh test. Their compensation is based on how much product they can move, not on appropriateness of prescription. And no study funded by a drug company can ever be trusted.

Allen Frances is a psychiatrist and professor emeritus, Duke University.  He blogs at the Huffington Post.

Prev

What is a serious diagnosis?

February 5, 2015 Kevin 8
…
Next

Top stories in health and medicine, February 6, 2015

February 6, 2015 Kevin 0
…

Tagged as: Medications, Psychiatry

Post navigation

< Previous Post
What is a serious diagnosis?
Next Post >
Top stories in health and medicine, February 6, 2015

More by Allen Frances, MD

  • #MeToo shows why women must learn sexual self-defense

    Allen Frances, MD
  • The problem of polypharmacy in psychiatry

    Allen Frances, MD
  • Pay primary care doctors what they’re worth

    Allen Frances, MD

More in Meds

  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Caught in the middle: How health insurance companies influence cancer drug selection

    Paul Pender, MD
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Why it’s time to question medical traditions [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden gems of health care: Unlocking the potential of narrative medicine

      Dr. Najat Fadlallah | Physician
    • The realities of immigrant health care served hot from America’s melting pot

      Stella Cho | Policy
    • The dark side of immortality: What if we could live forever?

      Ketan Desai, MD, PhD | Physician
    • Lazarus: the dead man brought back to life

      William Lynes, MD | Conditions
    • Revolutionizing COPD management with virtual care solutions [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 22 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Doc Moms, Mind the Gap -- $3M Earning Difference by Sex
  • Clinical Note Writing App Powered by GPT-4 Set to Debut This Year
  • Helping Patients Get Fit -- One Walk at a Time
  • TB Cases Rebound to Near Pre-Pandemic Levels, CDC Data Show
  • Marginalized Groups May Benefit More From Decreasing Air Pollution

Meeting Coverage

  • Switch to IL-23 Blocker Yields Deep Responses in Recalcitrant Plaque Psoriasis
  • Biomarkers of Response With Enfortumab Vedotin in Advanced Urothelial Cancer
  • At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks
  • Outlook for Itchy Prurigo Nodularis Continues to Improve With IL-31 Antagonist
  • AAAAI President Shares Highlights From the 2023 Meeting
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Why it’s time to question medical traditions [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden gems of health care: Unlocking the potential of narrative medicine

      Dr. Najat Fadlallah | Physician
    • The realities of immigrant health care served hot from America’s melting pot

      Stella Cho | Policy
    • The dark side of immortality: What if we could live forever?

      Ketan Desai, MD, PhD | Physician
    • Lazarus: the dead man brought back to life

      William Lynes, MD | Conditions
    • Revolutionizing COPD management with virtual care solutions [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Prescribing off-label: It’s gotten out of control
22 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...